Evidence map›Paper›PMID 40057763›Full record

ArticleCardiovascular diabetology2025

Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses.

Hsuan-Wen Lai, Jui-Yi Chen, Vin-Cent Wu, Chun Yin See

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Hsuan-Wen LaiSchool of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Jui-Yi ChenDivision of Nephrology, Department of Internal Medicine, Chi Mei Medical Centre, Tainan, Taiwan.
Vin-Cent WuDivision of Nephrology, Primary Aldosteronism Centre of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chun Yin SeeDivision of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , Tainan, Taiwan. seechunyin99@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2022 KDIGO guideline for diabetes management in patients with chronic kidney disease (CKD) had endorsed the use of GLP-1 receptor agonists (GLP-1RAs) for patients with CKD and type 2 diabetes who did not achieve optimal glycemic target with maximally tolerated metformin and sodium-glucose co-transporter-2 (SGLT-2) inhibitor. Our study revealed the potential benefits of GLP-1RAs in patients with dialysis-requiring acute kidney disease possibly owing to pleiotropic effects of the medicine. Nonetheless, pharmacokinetics and dialysis dose were omitted in our subgroup analyses. Herein, we would like to raise our concern regarding neglecting these important confounders in our analyses and the impact to the findings of the study.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Diabetic NephropathiesGlucagon-Like Peptide-1 Receptor AgonistsGlycemic ControlHypoglycemic AgentsIncretinsRenal DialysisRenal Insufficiency, ChronicAgedBiomarkersFemaleGlucagon-Like Peptide-1 ReceptorHumansMaleMiddle AgedBiomarkersBlood GlucoseGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsDialysisGLP-1 receptor agonistPharmacokineticsType 2 diabetes

Identifiers

PMID40057763
PMCPMC11890503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.